Reviva Pharmaceuticals Holdings, Inc. (RVPH) Balance Sheet
RVPH balance sheet, 2025
December 31, 2025 · U.S. dollars$15.9M assets = $7.3M liabilities + $8.6M equity
Both columns are drawn to the same scale: what RVPH owns equals what it owes plus shareholders’ equity. Hover a block for its value.
RVPH financial health
Descriptive bands, not a rating. Fiscal 2025.
RVPH balance sheet trends, 2018–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $65.2M2018 | $15.9M2025 | −18.2%/yr | |
| Total liabilities | $6.1M2018 | $7.3M2025 | +2.6%/yr | |
| Shareholders’ equity | $59.2M2018 | $8.6M2025 | −24.0%/yr | |
| Cash & short-term investments | $65.2M2018 | $14.4M2025 | −19.4%/yr | |
| Total debt | $3.8M2019 | $406,8752025 | −31.0%/yr | |
| Net cash (debt) | −$3.8M2019 | $14.0M2025 | +$17.8M | |
| Working capital | $59.2M2018 | $7.8M2025 | −$51.3M | |
| Current ratio | 10.722018 | 2.082025 | −8.64 | |
| Debt / equity | 0.562024 | 0.052025 | −0.52 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
RVPH assets
RVPH liabilities and equity
RVPH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
RVPH balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & short-term investments | $14.4M | $13.5M | $23.4M | $18.5M | $29.7M | $8.8M | $193 | $65.2M |
| Cash & equivalents | $14.4M | $13.5M | $23.4M | $18.5M | $29.7M | $8.8M | $193 | — |
| Short-term investments | — | — | — | — | — | — | $65.2M | $65.2M |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $664,685 | $1.2M | $332,932 | $403,819 | $1.7M | $0 | $0 | $0 |
| Total current assets | $15.1M | $14.7M | $23.7M | $18.9M | $31.4M | $8.8M | $193 | $65.2M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $591 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $819,721 | $819,721 | $0 | $0 | $0 | $1,816 | $1,816 | $0 |
| Total assets | $15.9M | $15.5M | $23.7M | $18.9M | $31.4M | $8.8M | $2,600 | $65.2M |
| Liabilities | ||||||||
| Accounts payable | $3.0M | $6.3M | $3.8M | $3.5M | $509,583 | $1.0M | $224,543 | $66,371 |
| Short-term debt | $406,875 | $458,154 | — | — | — | — | $3.8M | — |
| Deferred revenue | — | — | — | — | — | — | $2.7M | — |
| Total current liabilities | $7.3M | $14.6M | $17.2M | $10.0M | $2.3M | $1.3M | $100,102 | $6.1M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $89,010 | $806,655 | $567,439 | $372,730 | $2.0M | $2.2M | $0 |
| Total liabilities | $7.3M | $14.7M | $18.0M | $10.5M | $2.7M | $3.3M | $6.8M | $6.1M |
| Shareholders' equity | ||||||||
| Common stock & paid-in capital | $11,655 | $4,658 | $2,792 | $2,045 | $1,443 | $923 | $618 | $618 |
| Retained earnings (deficit) | −$184.1M | −$164.3M | −$134.4M | −$95.1M | −$66.8M | −$58.3M | −$54.5M | −$53.7M |
| Accumulated other comprehensive income | — | — | — | — | — | — | −$54.5M | — |
| Total shareholders' equity | $8.6M | $812,572 | $5.7M | $8.4M | $28.7M | $5.5M | −$6.8M | $59.2M |
| Key figures | ||||||||
| Total debt | $406,875 | $458,154 | — | — | — | — | $3.8M | — |
| Net cash (debt) | $14.0M | $13.0M | — | — | — | — | −$3.8M | — |
| Working capital | $7.8M | $81,861 | $6.5M | $9.0M | $29.1M | $7.4M | −$99,909 | $59.2M |
| Tangible book value | $8.6M | $812,572 | $5.7M | $8.4M | $28.7M | $5.5M | −$6.8M | $59.2M |
| Book value per share | $2.38 | — | — | — | — | — | — | — |
| Shares outstanding | 3.6M | — | — | — | — | — | — | — |
| Current ratio | 2.08 | 1.01 | 1.38 | 1.90 | 13.39 | 6.57 | 0.00 | 10.72 |
| Quick ratio | 1.98 | 0.92 | 1.36 | 1.86 | 12.66 | 6.57 | 0.00 | 10.72 |
| Debt / equity | 0.05 | 0.56 | — | — | — | — | — | — |
| Equity / assets | 54.3% | 5.2% | 24.1% | 44.4% | 91.3% | 62.4% | −261,978.1% | 90.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $19.89T | $22.2M | $14.4M | $13.2M | $10.4M | $5.3M | $13.5M | $5.6M | $6.2M | $12.0M | $23.4M | $5.0M |
| Cash & equivalents | $19.89T | $22.2M | $14.4M | $13.2M | $10.4M | $5.3M | $13.5M | $5.6M | $6.2M | $12.0M | $23.4M | $5.0M |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $1.25T | $1.4M | $664,685 | $329,669 | $451,411 | $967,921 | $1.2M | $1.3M | $1.1M | $1.5M | $332,932 | $414,743 |
| Total current assets | $21.14T | $23.6M | $15.1M | $13.5M | $10.8M | $6.3M | $14.7M | $6.8M | $7.2M | $13.5M | $23.7M | $5.4M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $819,721 | $819,721 | $819,721 | $819,721 | $819,721 | $819,721 | $819,721 | $0 | $0 | $0 |
| Total assets | $21.14T | $23.6M | $15.9M | $14.3M | $11.6M | $7.1M | $15.5M | $7.6M | $8.1M | $13.5M | $23.7M | $5.4M |
| Liabilities | ||||||||||||
| Accounts payable | $2.46T | $2.1M | $3.0M | $5.4M | $5.0M | $4.7M | $6.3M | $8.8M | $4.7M | $5.7M | $3.8M | $5.3M |
| Short-term debt | $144.09B | $231,274 | $406,875 | — | $113,246 | $224,300 | — | $83,000 | $207,500 | $332,000 | — | $222,500 |
| Total current liabilities | $5.93T | $6.1M | $7.3M | $9.7M | $12.1M | $11.5M | $14.6M | $17.5M | $13.9M | $14.5M | $17.2M | $13.0M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $44,506 | $16,690 | $27,816 | $89,010 | $77,884 | $150,205 | $350,478 | $806,655 | $873,411 |
| Total liabilities | $5.93T | $6.1M | $7.3M | $9.8M | $12.1M | $11.5M | $14.7M | $17.6M | $14.1M | $14.8M | $18.0M | $13.9M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $12.38B | $12,348 | $11,655 | $9,618 | $6,800 | $4,674 | — | $3,344 | $2,982 | $2,792 | — | $2,265 |
| Retained earnings (deficit) | −$189.78T | −$187.3M | −$184.1M | −$180.8M | −$176.8M | −$170.7M | −$164.3M | −$158.0M | −$149.6M | −$141.8M | −$134.4M | −$120.7M |
| Total shareholders' equity | $15.21T | $17.4M | $8.6M | $4.5M | −$459,147 | −$4.5M | $812,572 | −$10.0M | −$6.0M | −$1.3M | $5.7M | −$8.5M |
| Key figures | ||||||||||||
| Total debt | $144.09B | $231,274 | $406,875 | — | $113,246 | $224,300 | — | $83,000 | $207,500 | $332,000 | — | $222,500 |
| Net cash (debt) | $19.75T | $22.0M | $14.0M | — | $10.3M | $5.1M | — | $5.5M | $6.0M | $11.6M | — | $4.7M |
| Working capital | $15.21T | $17.4M | $7.8M | $3.8M | −$1.3M | −$5.3M | $81,861 | −$10.7M | −$6.7M | −$995,339 | $6.5M | −$7.6M |
| Tangible book value | $15.21T | $17.4M | $8.6M | $4.5M | −$459,147 | −$4.5M | $812,572 | −$10.0M | −$6.0M | −$1.3M | $5.7M | −$8.5M |
| Book value per share | $1,151,279.05 | $2.48 | $2.38 | $1.25 | — | — | — | — | — | — | $0.20 | — |
| Shares outstanding | 13.2M | 7.0M | 3.6M | 3.6M | — | — | — | — | — | — | 27.9M | — |
| Current ratio | 3.56 | 3.85 | 2.08 | 1.39 | 0.90 | 0.54 | 1.01 | 0.39 | 0.52 | 0.93 | 1.38 | 0.41 |
| Quick ratio | 3.35 | 3.63 | 1.98 | 1.35 | 0.86 | 0.46 | 0.92 | 0.32 | 0.44 | 0.83 | 1.36 | 0.38 |
| Debt / equity | 0.01 | 0.01 | 0.05 | — | — | — | — | — | — | — | — | — |
| Equity / assets | 71.9% | 74.0% | 54.3% | 31.7% | −3.9% | −63.0% | 5.2% | −130.8% | −75.0% | −10.0% | 24.1% | −158.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 30, 2026); data from EODHD.
RVPH financial position
At the end of fiscal 2025 (December 31, 2025), Reviva Pharmaceuticals had total assets of $15.9 million (up 2.7% from a year earlier), total liabilities of $7.3 million and shareholders' equity of $8.6 million. It held $14.4 million in cash and short-term investments against $0.4 million of debt, a net cash position of $14.0 million. Its current ratio was 2.08. In the latest quarter (ended June 30, 2026) total assets were $21.14 trillion and equity $15.21 trillion.
Related: RVPH income statement, RVPH cash flow statement, RVPH key metrics. See the RVPH stock overview for the latest quote and news.
RVPH balance sheet FAQ
What are Reviva Pharmaceuticals's total assets?
Reviva Pharmaceuticals reported total assets of $15.9 million at the end of fiscal 2025 (December 31, 2025), compared with $15.5 million a year earlier.
How much debt does Reviva Pharmaceuticals have?
Reviva Pharmaceuticals had $0.4 million of total debt at the end of fiscal 2025, including short-term borrowings. Its debt-to-equity ratio was 0.05.
How much cash does Reviva Pharmaceuticals have?
Reviva Pharmaceuticals held $14.4 million in cash and short-term investments at the end of fiscal 2025; with $0.4 million of debt that is net cash of $14.0 million.
What is Reviva Pharmaceuticals's book value?
Reviva Pharmaceuticals's shareholders' equity (book value) was $8.6 million at the end of fiscal 2025, or $2.38 per share.
What is Reviva Pharmaceuticals's current ratio?
Reviva Pharmaceuticals had current assets of $15.1 million and current liabilities of $7.3 million, a current ratio of 2.08 (it can cover its short-term obligations).